Journal of diabetes and its complications最新文献

{"title":"Nonlinear association of the hemoglobin glycation index with all-cause and cardiovascular mortality: A community-based cohort study","authors":"Junchen He ,&nbsp;Haodong Zhang ,&nbsp;Yinxi Tan ,&nbsp;Huangda Guo ,&nbsp;Hexiang Peng ,&nbsp;Yi Zheng ,&nbsp;Lunrongyi Tian ,&nbsp;Xinru Liu ,&nbsp;Yiqun Wu ,&nbsp;Xueying Qin ,&nbsp;Haiying Gong ,&nbsp;Yao Zhao ,&nbsp;Weifeng Wu ,&nbsp;Tao Wu ,&nbsp;Dafang Chen ,&nbsp;Yonghua Hu ,&nbsp;Mengying Wang","doi":"10.1016/j.jdiacomp.2025.109212","DOIUrl":"10.1016/j.jdiacomp.2025.109212","url":null,"abstract":"<div><h3>Background</h3><div>The hemoglobin glycation index (HGI) has been increasingly recognized for predicting cardiovascular outcomes. However, its association with all-cause and cardiovascular disease (CVD) mortality in the general population remains underexplored. This study aimed to investigate the nonlinear relationship between the HGI and mortality, identify risk thresholds, and evaluate HGI's clinical utility for individualized risk stratification.</div></div><div><h3>Methods</h3><div>4857 participants from the Fangshan Family-based Ischemic Stroke Study in China (FISSIC) were included. Death dates were obtained by reviewing the death certificates until 2024/7/31. During a median follow-up of 8 years, 652 deaths were identified, including 379 deaths due to CVD. HGI was calculated as <em>HGI = Observed hemoglobin A1c (HbA1c) − Predicted HbA1c</em>. Cox proportional hazard regression models and restricted cubic splines were constructed to assess the relationship of HGI with mortality risk.</div></div><div><h3>Results</h3><div>This study revealed a J-shaped association of HGI with both all-cause and CVD mortality. For all-cause mortality, when HGI was below the threshold point (−0.58), the mortality risk slightly decreased with increasing HGI, with a hazard ratio (HR) of 0.821 (95 %CI: 0.666–1.011, <em>P</em> = 0.064). Conversely, when HGI exceeded −0.58, the mortality risk significantly increased with higher HGI (HR: 1.193, 95 % CI: 1.104–1.289, <em>P</em> &lt; 0.001). CVD mortality exhibited similar threshold effects, with HGI &lt; −0.58 trended toward lower risk (HR: 0.80, 95 %CI: 0.60–1.06, <em>P</em> = 0.114), whereas HGI &gt; −0.58 showed marked risk elevation (HR: 1.23, 95 %CI: 1.11–1.36, <em>P</em> &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>This study demonstrates a nonlinear relationship of HGI with both all-cause and CVD mortality.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 1","pages":"Article 109212"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145495746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of oral alpha-lipoic acid as an adjuvant antioxidant therapy in diabetic nephropathy among children and adolescents with type 1 diabetes: a randomized controlled trial","authors":"Yasmine Ibrahim Elhenawy ,&nbsp;Rasha Adel Thabet ,&nbsp;Marwa G.A. Hegazy ,&nbsp;Shymaa Ayed El-Morsy ,&nbsp;Yasmeen AbdelAziz Fereig","doi":"10.1016/j.jdiacomp.2025.109201","DOIUrl":"10.1016/j.jdiacomp.2025.109201","url":null,"abstract":"<div><h3>Aim</h3><div>Evaluate the oxidant-antioxidant balance and the efficacy of Alpha-lipoic acid (ALA) as an adjuvant therapy for diabetic nephropathy (DN) among individuals with type 1 diabetes (T1D).</div></div><div><h3>Materials and methods</h3><div>A 3 months prospective randomized controlled trial including 50 participants with DN randomly allocated (1:1) to one of two arms; an interventional arm receiving 300 mg/day of ALA (<em>n</em> = 25) and a non-interventional arm (n = 25). Initial assessments included HbA1c, urinary albumin excretion rate (UAER), malondialdehyde (MDA), and total antioxidant capacity (TAC). Baseline data was compared with 50 participants with T1D without DN and 50 healthy controls.</div></div><div><h3>Results</h3><div>T1D participants had significantly higher MDA and lower TAC levels compared to controls (<em>P</em> &lt; 0.01). Within the T1D cohort, participants with DN showed significantly higher MDA and lower TAC levels (<em>P</em> &lt; 0.01). MDA positively correlated with triglycerides (<em>r</em> = 0.53), UAER (<em>r</em> = 0.70), and HbA1c (r = 0.5) (<em>p</em> &lt; 0.01), while TAC negatively correlated triglycerides (<em>r</em> = −0.41), UAER (<em>r</em> = −0.88), and HbA1c (<em>r</em> = −0.64) (<em>p</em> &lt; 0.01). After 3 months of ALA supplementation, significant reductions in HbA1c, UAER, and MDA were observed, along with an increase in TAC (<em>P</em> &lt; 0.01).</div></div><div><h3>Conclusion</h3><div>The study demonstrates that 3 months of ALA supplementation effectively reduced oxidative stress and UAER, demonstrating a potential role in protecting renal tissue from diabetes-induced oxidative damage.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 1","pages":"Article 109201"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145452046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Data-driven subtypes of newly diagnosed youth-onset type 2 diabetes in the USA","authors":"Jiali Guo ,&nbsp;Zhongyu Li ,&nbsp;Rodrigo M. Carrillo-Larco ,&nbsp;Daniel S. Hsia ,&nbsp;Jessica L. Harding ,&nbsp;Mohammed K. Ali ,&nbsp;Jithin Sam Varghese","doi":"10.1016/j.jdiacomp.2025.109207","DOIUrl":"10.1016/j.jdiacomp.2025.109207","url":null,"abstract":"<div><h3>Aims</h3><div>To identify subtypes of newly diagnosed youth-onset T2D using cluster analysis.</div></div><div><h3>Methods</h3><div>A cross-sectional study included participants with T2D (duration ≤1 year) aged 10–19 years from the SEARCH for Diabetes in Youth Study (<em>n</em> = 304; 47.4 %) and aged 10–17 years from the Treatment Options for Type 2 Diabetes in Adolescents and Youth (<em>n</em> = 337; 52.6 %) study before intervention allocation. We examined variables available in routine clinical practice. Main outcomes were data-driven subtypes identified using k-means clustering.</div></div><div><h3>Results</h3><div>Among 641 participants with youth-onset T2D, 58.2 % were female. The analysis revealed three youth-onset subtypes: 48.5 % had obesity-related T2D (yOD), 18.7 % had insulin deficient T2D (yIDD), and 32.7 % had insulin resistant T2D (yIRD). The yOD subtype was characterized by high BMI and low HbA1c. The yIDD exhibited low fasting C-peptide levels, high HDL cholesterol, and high HbA1c. The yIRD subtype had high BMI, high fasting C-peptide, and high blood pressures compared to other subtypes. A higher prevalence of distal symmetric polyneuropathy was observed at diagnosis among yIDD and yIRD subtypes, relative to the yOD subtype.</div></div><div><h3>Conclusions</h3><div>Three subtypes of youth-onset T2D were identified with different clinical characteristics. Management of youth-onset T2D may require tailored strategies by subtype.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 1","pages":"Article 109207"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145445093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of biomarkers to predict renal function decline and its deceleration in patients with type 2 diabetes and diabetic kidney disease","authors":"Motonobu Nishimura ,&nbsp;Kazuya Yonezawa ,&nbsp;Morio Sawamura ,&nbsp;Tsuyoshi Tanaka ,&nbsp;Yuichi Yamamoto ,&nbsp;Hideki Taki ,&nbsp;Masako Hatao ,&nbsp;Masaya Takeda ,&nbsp;Kazuyuki Hida ,&nbsp;Junko Koide ,&nbsp;Miho Saito ,&nbsp;Nobuyuki Koriyama ,&nbsp;Tomokazu Watanabe ,&nbsp;Ryo Nakajima ,&nbsp;Yoshiharu Hoshiyama","doi":"10.1016/j.jdiacomp.2025.109208","DOIUrl":"10.1016/j.jdiacomp.2025.109208","url":null,"abstract":"<div><h3>Aims</h3><div>This study aimed to identify noninvasive biomarkers for predicting the effectiveness of multifactorial management in individual cases of diabetic kidney disease (DKD).</div></div><div><h3>Methods</h3><div>This multicenter, retrospective–prospective observational study included patients with type 2 diabetes and DKD. Candidate biomarkers were evaluated within 1 year of enrollment. Deceleration in the rate of decline in the estimated glomerular filtration rate (eGFR) was defined as an indicator of prognostic improvement in DKD. The correlation between candidate biomarkers and baseline eGFR, as well as with eGFR decline, was analyzed. Furthermore, candidate biomarkers were compared between the groups with and without a deceleration in eGFR decline.</div></div><div><h3>Results</h3><div>Serum soluble thrombomodulin (sTM) levels, urinary liver-type fatty acid-binding protein excretion, kidney size, and renal surface irregularities were found to be independently associated with baseline eGFR. Serum sTM levels and urinary type IV collagen excretion were independently associated with eGFR decline. Furthermore, the eGFR decline rate during the first 2 years of the observation period was independently associated with the later deceleration of eGFR decline. Additionally, the probability of deceleration in eGFR decline was higher among patients who experienced a more rapid eGFR decline early in the observation period. However, a biomarker that could predict the likelihood of deceleration in eGFR decline could not be identified.</div></div><div><h3>Conclusions</h3><div>We identified four noninvasive biomarkers that independently correlated with the eGFR, among which urinary type IV collagen excretion and serum sTM levels were particularly useful in predicting eGFR decline.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 1","pages":"Article 109208"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145458822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Soluble tumor necrosis factor receptors (sTNFRs) as biomarkers for diabetic kidney disease","authors":"Emily Moroney ,&nbsp;Monika A. Niewczas ,&nbsp;Elif I. Ekinci ,&nbsp;Richard J. MacIsaac","doi":"10.1016/j.jdiacomp.2025.109204","DOIUrl":"10.1016/j.jdiacomp.2025.109204","url":null,"abstract":"<div><div>Multiple biomarkers have been associated with Diabetic Kidney Disease (DKD) progression and its associated exaggerated risk for cardiovascular events and mortality. Chronic inflammation plays an important role in the progression of DKD. Tumour Necrosis Factor alpha (TNF-α) is a central proinflammatory cytokine that binds to its soluble receptor (sTNFR) and has been implicated in the pathogenesis of DKD. sTNFRs are a family of membrane proteins that regulate gene expression and activate cell death pathways. They are involved in the immune system and can bind to cytokines related to TNF. Higher levels of the type 1 (sTNFR1) and type 2 (sTNFR2) receptor have consistently been associated with progressive DKD, notably rapid GFR decline and progression to kidney failure. They offer enhanced risk prediction for progressive DKD over and above established risk markers. Higher levels of sTNFR1 and sTNFR2 also predict incident cardiovascular disease and mortality in people with diabetes. Further studies are required to define the temporal relationship between changes in circulating sTNFR levels and progression of kidney function loss. The influence of medications with kidney protective effects on sTNFR levels also requires further investigation.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 1","pages":"Article 109204"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145420257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age at type 2 diabetes diagnosis and risk of cancer: Cohort study in over 1 million individuals from the TriNetX US Collaborative Network","authors":"Tommy Slater ,&nbsp;Gema Hernández Ibarburu ,&nbsp;Zuzanna Drebert ,&nbsp;Joseph Henson ,&nbsp;Jonathan Goldney ,&nbsp;Francesco Zaccardi ,&nbsp;Jack A. Sargeant ,&nbsp;Karen Brown ,&nbsp;David R. Webb ,&nbsp;Dimitris Papamargaritis ,&nbsp;Juliana C.N. Chan ,&nbsp;Edward W. Gregg ,&nbsp;Kamlesh Khunti ,&nbsp;Melanie J. Davies ,&nbsp;Thomas Yates","doi":"10.1016/j.jdiacomp.2025.109210","DOIUrl":"10.1016/j.jdiacomp.2025.109210","url":null,"abstract":"<div><h3>Aims</h3><div>To investigate whether the association between type 2 diabetes diagnosis and relative and absolute risk of obesity-related cancers differs based on age at diabetes diagnosis.</div></div><div><h3>Methods</h3><div>This retrospective, observational cohort study used data from the US Collaborative Network within the TriNetX database. Individuals with type 2 diabetes were propensity matched – for age, sex, and ethnicity – to individuals without type 2 diabetes. Crude 5-year risks of obesity-related cancer were calculated. Cox proportional-hazards models were used to assess relative rates of obesity-related cancer incidence over five years, comparing individuals with type 2 diabetes in younger (aged ≤40 years; <em>n</em> = 162,691) and middle-older age (aged &gt;40 years; <em>n</em> = 1,616,950), with propensity-matched cohorts without type 2 diabetes.</div></div><div><h3>Results</h3><div>Absolute risk of developing cancer was greater in individuals with versus without type 2 diabetes. Relative rates of any cancer were greater in younger (HR: 2·01 [95 % CI: 1·85, 2·19]) than middle-older age adults (1·49 [1·48, 1·51]). The highest relative rates in younger adults were observed for corpus uteri (HR: 4·76 [3·51, 6·46]) and pancreatic cancer (4·25 [2·34, 7·72]). Corresponding HRs in middle-older age adults were 1·92 (1·84, 2·01) and 1·75 (1·68, 1·83).</div></div><div><h3>Conclusions</h3><div>The five-year risk of cancer was higher in those with newly diagnosed type 2 diabetes versus those without. Absolute risk was greater in middle-older age adults, although relative rates were greater amongst younger adults. This persisted across most site-specific cancers, suggesting targeted strategies for early detection and prevention may help younger adults with newly-diagnosed type 2 diabetes reduce lifetime disease burden.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 1","pages":"Article 109210"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145513015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regenerative medicine approaches for treating diabetes: Current advances and future directions","authors":"Sanja Medenica ,&nbsp;Dzihan Abazovic ,&nbsp;Jovana Vukovic ,&nbsp;Tanja Vojinovic ,&nbsp;Filip Tomovic ,&nbsp;Giuseppe Defeudis ,&nbsp;Rossella Mazzilli ,&nbsp;Zlata Kovacevic ,&nbsp;Dusan Djurdjic ,&nbsp;Vladimir Prelevic ,&nbsp;Tanja Abazovic ,&nbsp;Manfredi Rizzo ,&nbsp;Essam M. Abdelalim","doi":"10.1016/j.jdiacomp.2025.109232","DOIUrl":"10.1016/j.jdiacomp.2025.109232","url":null,"abstract":"<div><div>Diabetes mellitus, a chronic metabolic disorder characterized by hyperglycemia, has become a global health issue. The disease primarily presents as type 1 diabetes (T1D), caused by autoimmune β-cell destruction; type 2 diabetes (T2D), driven by insulin resistance and β-cell dysfunction; and monogenic diabetes, resulting from single-gene mutations affecting insulin production or β-cell function. Chronic hyperglycemia increases the risk of severe complications, including cardiovascular disease, neuropathy, and kidney failure. Despite advancements in insulin therapy and glucose monitoring, no cure currently exists for diabetes, with treatments mainly focused on managing symptoms rather than addressing the underlying β-cell loss. Regenerative medicine offers new hope, particularly through β-cell replacement strategies such as islet and stem cell-derived β-cell transplantation. Advances in generating hypoimmunogenic stem cell-derived pancreatic β-cells may help overcome immune rejection and donor shortages. These therapies have shown promise in clinical trials for both T1D and T2D. Furthermore, pharmacological strategies targeting β-cell regeneration show promise in enhancing β-cell proliferation and function. This review highlights the significant advancements in regenerative approaches for diabetes, underscoring the potential for long-term management and, ultimately, a cure for diabetes in the future.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 1","pages":"Article 109232"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145615455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glycemia, management and outcomes of pregnant women with maturity-onset diabetes of the young – a single-center case series","authors":"Isabella Lindegaard Jørgensen ,&nbsp;Anne Cathrine Baun Thuesen ,&nbsp;Tine Dalsgaard Clausen ,&nbsp;Lene Ringholm ,&nbsp;Elisabeth R. Mathiesen ,&nbsp;Torben Hansen ,&nbsp;Peter Damm","doi":"10.1016/j.jdiacomp.2025.109206","DOIUrl":"10.1016/j.jdiacomp.2025.109206","url":null,"abstract":"<div><h3>Aims</h3><div>At Rigshospitalet, Copenhagen, Denmark, pregnancy management for women with GCK-MODY is guided by markedly elevated glucose levels and fetal overgrowth, while management for women with HNF1A-MODY follows guidelines for type 1 and type 2 diabetes. We aimed to evaluate current treatment strategies for pregnant women with GCK- or HNF1A-MODY.</div></div><div><h3>Methods</h3><div>We conducted a retrospective population-based cohort study of 18 consecutive pregnancies in 11 women with GCK-MODY and 17 consecutive pregnancies in 11 women with HNF1A-MODY, matched with 140 pregnancies in 133 women with type 2 diabetes, referred to Rigshospitalet, Copenhagen, between June 2011 and December 2023. Glycemia, pregnancy- and perinatal outcomes were compared using generalized estimating equation models.</div></div><div><h3>Results</h3><div>In pregnancies in women with GCK-MODY, median HbA1c levels remained stable from early in pregnancy (&lt; 20 weeks) to late in pregnancy (45 to 46 mmol/mol), while decreasing in pregnancies in women with HNF1A-MODY (41 to 37 mmol/mol) and type 2 diabetes (47 to 41 mmol/mol). The prevalence of hypertensive disorders (5.6 vs. 35.0 %), preterm delivery (0 % vs. 17.9 %), and large for gestational age (16.7 % vs. 35.7 %), were lower in pregnancies in women with GCK-MODY compared to type 2 diabetes, though not statistically significant. Pregnancy- and perinatal outcomes were comparable between pregnancies in women with HNF1A-MODY and type 2 diabetes.</div></div><div><h3>Conclusions</h3><div>In women with GCK-MODY, pregnancy outcomes were reassuring supporting the current treatment strategy. In women with HNF1A-MODY, guidelines for type 1 and type 2 diabetes resulted in glycemic control within target and pregnancy outcomes similar to type 2 diabetes.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 1","pages":"Article 109206"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145445117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum analysis of type 2 diabetes mellitus patients with low, moderate, and high risk of diabetic kidney disease using LC-MS metabolomics approach","authors":"Salwa Dilfari Pohan ,&nbsp;Rani Sauriasari ,&nbsp;Baitha Palanggatan Maggadani ,&nbsp;Taufiq Indra Rukmana ,&nbsp;Farah Mahdiyah ,&nbsp;Fathia Yusrina ,&nbsp;Sri Hayati ,&nbsp;Richard Johari James ,&nbsp;Mohd Salleh Rofiee ,&nbsp;Teh Lay Kek ,&nbsp;Mohd Zaki Salleh","doi":"10.1016/j.jdiacomp.2025.109202","DOIUrl":"10.1016/j.jdiacomp.2025.109202","url":null,"abstract":"<div><h3>Objectives</h3><div>This study investigated the relationship between serum metabolomic profiles and diabetic kidney disease (DKD) risk in patients with type 2 diabetes mellitus (T2DM) stratified into three KDIGO-defined risk categories.</div></div><div><h3>Methods</h3><div>Serum samples from 48 patients were analyzed using untargeted liquid chromatography–quadrupole time-of-flight mass spectrometry (LC-QTOF/MS). Participants were classified into low (<em>n</em> = 16), moderate (n = 16), and high (n = 16) DKD risk groups according to KDIGO guidelines. Differential metabolites were identified based on <em>p</em>-value, log fold change, and variable importance in projection (VIP), and subsequently subjected to pathway enrichment analysis.</div></div><div><h3>Results</h3><div>Comparative analysis revealed five differential metabolites between low- and moderate-risk groups, three between moderate- and high-risk groups, and three between low- and high-risk groups. Notably, sphinganine, arachidonic acid, and ornithine were progressively downregulated, whereas AFMK, L-arginine, lactosylceramide (LacCer), and lysophosphatidylcholine (lysoPC) were upregulated with increasing DKD risk. These metabolites mapped to disturbed pathways, including arginine and proline metabolism, sphingolipid metabolism, glycerophospholipid metabolism, arachidonic acid metabolism, and tryptophan metabolism.</div></div><div><h3>Conclusion</h3><div>This study highlights progressive alterations in amino acid, lipid, and inflammatory pathways across DKD risk categories, suggesting that these stage-specific metabolomic signatures may serve as putative biomarkers for detection and monitoring of DKD progression in T2DM.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 1","pages":"Article 109202"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145569414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of technologies on quality of life in relation to glucose control in patients with type 1 diabetes","authors":"Silvia Irina Briganti ,&nbsp;Oreste Lanza ,&nbsp;Valerio Renzelli ,&nbsp;Giuseppe Campagna ,&nbsp;Daria Maggi ,&nbsp;Massimiliano Caprio ,&nbsp;Silvia Manfrini ,&nbsp;Rocky Strollo","doi":"10.1016/j.jdiacomp.2025.109215","DOIUrl":"10.1016/j.jdiacomp.2025.109215","url":null,"abstract":"<div><h3>Aim</h3><div>To assess the effect of insulin delivery and glucose monitoring technologies on quality of life in relation with glucose control in adults with type 1 diabetes (T1D).</div></div><div><h3>Methods</h3><div>This cross-sectional study included 69 adults with T1D (mean age 39.3 ± 12.1 years; 44.9 % females): 36 on multiple daily insulin injections (MDI) and 33 on continuous subcutaneous insulin infusion (CSII). Patient-reported outcomes were assessed using the Diabetes Treatment Satisfaction Questionnaire (DTSQ), Diabetes-Specific Quality of Life Scale (DSQOLS), and SF-36. Glucose control was evaluated using HbA1c and CGM metrics.</div></div><div><h3>Results</h3><div>Individuals in the CSII group reported higher treatment-related satisfaction (<em>p</em> = 0.004), and better disease acceptance (p = 0.004) compared with individuals on MDI, despite similar age, sex or disease duration (<em>p</em> &gt; 0.34). Time in range (TIR) resulted higher in the CSII group than in the MDI group (<em>p</em> = 0.02), while time below range (TBR) resulted higher in the MDI group compared to CSII (<em>p</em> = 0.03). Individuals reporting high satisfaction scores demonstrated better glucose control metrics compared to those with lower satisfaction levels. The association between satisfaction and TIR was relevant, even after adjusting for treatment modality (<em>p</em> = 0.0003).</div></div><div><h3>Conclusions</h3><div>Technology may improve quality of life over MDI treatment. Improvement in glucose control may partially account for this effect.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 1","pages":"Article 109215"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145518206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}